The partnership is also expected to see an investment by KT in NeuroSigma
Monarch Pulse Generator and Patch. (Credit: NeuroSigma, Inc.)
Los Angeles-based bioelectronics company NeuroSigma has partnered with South Korea’s telecom company KT for the development of new electronic therapies.
Under the partnership, the two companies will work together to develop and commercialise electronic therapies inside and outside of Korea.
The therapies will be aimed at treating neurological and neuropsychological disorders, including attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
KT’s future value promotion office head Kim Hyung-wook said: “In Korea, digital therapy is still in its infancy, but its utility and growth potential are excellent.
“Starting with our strategic partnership with NeuroSigma, we will actively foster and promote digital therapeutics, including electronic drugs, as the basis of new and innovative healthcare businesses and to expand the digital therapeutics market in Korea and beyond.”
The Monarch eTNS System, which is developed by NeuroSigma, uses non-invasive external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications.
In April 2019, the system received clearance from the US Food and Drug Administration (FDA) as a non-drug treatment for pediatric ADHD.
NeuroSigma intends to carry out additional trials for label expansion of the Monarch eTNS System in ADHD. In addition, it plans to conduct pivotal trials for depression and epilepsy.
Under the partnership, KT will support the design and development of next-generation versions of eTNS products, with artificial intelligence (AI), big data, and cloud capabilities.
Through its digital healthcare platform, the telecom company will also provide advanced monitoring and AI analysis services for the development of the electronic therapies.
The partnership is also expected to see an investment by KT in NeuroSigma.
Kim added: “We have been impressed with NeuroSigma’s eTNS System, which has already shown itself to be a safe and effective alternative to drug-based therapies.
“We are eager to work with NeuroSigma to integrate this industry-leading digital therapy into our growing digital healthcare platform and to develop the next generations of digital therapy.”